Table 1 Patient demographics.

From: Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study

	Total		RAS and BRAFwt		RASmt		BRAFmt
	906	100%	289	100%	529	100%	88	100%
Age
Median years (range)	66.1	(24–88)	65.8	(24–88)	66.1	(25–88)	66.9	(33–83)
≤70	607	67%	201	70%	347	66%	59	67%
>70	299	33%	88	30%	182	34%	29	33%
Sex
Male	549	61%	195	68%^b	320	61%^b	34	39%^b
Female	357	39%	94	33%^b	209	40%^b	54	61%^b
ECOG
PS 0	260	29%	84	29%	157	30%	19	22%
PS 1	503	56%	160	55%	296	56%	47	53%
PS 2–3	143	16%	45	16%^c	76	14%^c	22	25%^c
Charlson comorbidity index
0	700	77%	226	78%	409	77%	65	74%
1–2	199	22%	60	21%	116	22%	23	26%
3–5	7	1%	3	1%	4	1%	0	0%
Body mass index
<20	64	7%	19	7%	40	8%	5	6%
20–30	674	74%	219	76%	392	74%	63	72%
≥30	168	19%	51	18%	97	18%	20	23%
Primary tumour location
Right colon	261	29%	45	16%^d	157	30%^d	59	67%^d
Left colon	330	36%	134	46%^d	181	34%^d	15	17%^d
Rectum	310	34%	108	37%^d	190	36%^d	12	14%^d
Multiple	5	1%	2	1%	1	0%	2	2%
Signet ring or mucinous carcinoma
No	269	93%	469	89%	805	89%	67	76%
Yes	20	7%^e	60	11%^e	101	11%^e	21	24%^e
Primary tumour resection
Upfront	604	67%	195	68%	350	66%	59	67%
During	96	11%	39	14%	51	10%	6	7%
No	206	23%	55	19%	128	24%	23	26%
Presentation of metastases
Synchronous^a	608	67%	180	62%	366	69%	62	71%
Metachronous	298	33%	109	38%	163	31%	26	30%
Adjuvant chemotherapy for primary tumour
No adjuvant	690	76%^f	205	71%^f	417	79%^f	68	77%^f
Fluoropyrimidine	91	10%	35	12%	51	10%	5	6%
Oxaliplatin based	125	14%	49	17%	61	12%	15	17%
Radiotherapy for rectum
No	192	62%	70	65%	115	61%	7	58%
Preop 5 × 5 Gy	46	15%	14	13%	32	17%	0	0%
Chemoradiation	54	17%	17	16%	33	17%	4	33%
Palliative	18	6%	7	6%	10	5%	1	8%
Metastatic sites
Single	483	53%	152	53%	285	54%	46	52%
Multiple	423	47%	137	47%	244	46%	42	48%
Location of metastases at baseline
Liver	675	75%	224	78%^g	394	74%^g	57	65%^g
Lung	278	31%	68	24%^h	185	35%^h	25	28%^h
Lymph nodes	235	26%	83	29%	123	23%	29	33%
Peritoneal	151	17%	43	15%ⁱ	80	15%ⁱ	28	32%ⁱ
Local relapse	55	6%	20	7%	26	5%	9	10%
Other	121	13%	50	17%	61	11%	10	11%

OR (95% CI), respectively, for RAS and BRAFwt /RASmt/BRAFmt.
^aWithin 2 months from the diagnosis of primary tumour.
^bFor female sex ref/1.4(1.0–1.8)/3.3(2.0–5.4).
^cFor ECOG PS 2–3 vs 0–1 ref/0.96(0.77–1.12)/1.5(1.0–2.1).
^dFor more right-sided tumours than left-sided or rectal (multifocal excluded) ref/2.3(1.6–3.3)/11.8(6.7–20.5).
^eFor signet ring or mucinous carcinoma ref/1.7(1.0–2.9)/4.2(2.2–8.2).
^fFor adjuvant therapy after resection of primary tumour ref/0.7(0.5–0.9)/0.7(0.4–1.3).
^gFor liver metastases more common ref/0.8(0.6–1.2)/0.5(0.3–0.6).
^hFor lung metastases more common ref/1.7(1.3–2.4)/1.3(0.8–2.2).
ⁱFor peritoneal metastases more common ref/1.0(0.7–1.5)/2.7(1.6–4.6).

Back to article page

Table 1 Patient demographics.

Search

Quick links